Depression and anxiety are often experienced at a higher rate in people with chronic diseases than the general population and those with rheumatoid arthritis (RA) are no exception.
At the recent American College of Rheumatology Conference, a study was presented that looked at the impact that depression and anxiety have on people living with RA. In those people whose depression and anxiety was not treated, they had less response to treatment, which resulted in higher levels of disease activity compared to people who did not have depression. This encourages those suffering from these conditions to seek treatment to receive the fullest benefit from their RA medications.
Our pharmacist, Carolyn Whiskin, recently returned from The American College of Rheumatology Conference, the largest international meeting held for rheumatology. Over 15,000 health professionals from around the world specializing in research and the care of people with arthritis were in attendance. Today’s blog post is one several to come with information Carolyn learned at the Conference.
Saphnelo (anifrolumab) is a one-of-a-kind therapy by AstraZeneca for the treatment of moderate to severe…
On December 4, 2023, Health Canada approved Pfizer’s Litfulo (ritlecitinib). Litfulo is a once-daily oral…
Infliximab is a protein-based medication referred to as a biologic that treats many immune-mediated conditions. …
On October 3rd, 2023, Health Canada approved Eli Lilly’s newest biologic for the treatment of…
As February is heart month, today is an excellent occasion to really show why we love our hearts and…
To better serve our Hamilton and area patients, we have expanded and moved our Stoney…